ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2016

Generation of a Human 3D in Vitro Bone Model That Mimics Glucocorticoid-induced Osteoporosis

Moritz Pfeiffenberger1, Johannes Plank1, Alexandra Damerau1, Timo Gaber1 and Frank Buttgereit2, 1Charité Universitatsmedizine - Berlin, Berlin, Germany, 2Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany

Meeting: ACR Convergence 2023

Keywords: bone biology, osteoporosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1996–2018) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Osteoporosis is a bone disease characterized by low bone mass and changes in bone architecture, leading to pain and reduced mobility in patients. Glucocorticoid-induced osteoporosis (GIOP) is the best known form of secondary osteoporosis. Glucocorticoids (GC) are commonly used to treat inflammation, such as in rheumatic diseases. However, GC use can have a negative effect on the skeletal system and lead to osteoporosis.

(i) Establishing and characterizing a human in vitro bone model consisting of osteoblasts and osteoclasts embedded in β-TCP (“healthy” bone model), (ii) treatment with dexamethasone to induce GIOP (“osteoporotic” bone model) and (iii) using this model as a testing platform for the treatment of osteoporosis.

Methods: Our model includes osteoblasts and osteoclasts, which are mainly responsible for bone remodeling. We defined an osteoclast differentiation protocol using low-attachment plates and cultured the cells for 21 days in ∝MEM medium, 5% FCS, 5% human AB serum, 2 mmol L-glutamine, 25 ng/ml M-CSF, and 50 ng/ml RANKL. To provide the basic scaffold for the structure of the “healthy” bone model, mesenchymal stromal cells (MSCs) were seeded on β-tricalcium phosphate (β-TCP). This bone model, consisting of differentiated osteogenic cells, was fully characterized in our previous work [1].

Results: The multinuclearity, typical ß-actin ring formation, cellular activity by TRAP staining and functionality in resorption assays proved functional osteoclasts. Our protocol allowed us to passage these cells without cell loss or loss of function. To establish the previously “healthy” (i.e., untreated) bone model, we seeded osteoclasts onto a pre-seeded β-TCP construct and cultured the co-culture for 7 days. We then analyzed the supernatant and detected marked secretion of RANKL, MMP-9, and free phosphate. This indicates the functionality of both osteoclasts and osteoblasts in our 3D model. Subsequently, the healthy model will be transferred to the osteoporosis-simulating model where treatment with dexamethasone will be applied. Once established, we plan to use the model we have developed for in vitro preclinical trials to test marketed drugs.

Conclusion: Ultimately, we will obtain an in vitro 3D co-culture of osteoblasts/osteoclasts simulating human native bone, which will be treated with dexamethasone to mimic key aspects of GIOP in vitro.


Disclosures: M. Pfeiffenberger: None; J. Plank: None; A. Damerau: None; T. Gaber: None; F. Buttgereit: AbbVie/Abbott, 6, Horizon Therapeutics, 5, Pfizer, 5, 6, Roche, 6.

To cite this abstract in AMA style:

Pfeiffenberger M, Plank J, Damerau A, Gaber T, Buttgereit F. Generation of a Human 3D in Vitro Bone Model That Mimics Glucocorticoid-induced Osteoporosis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/generation-of-a-human-3d-in-vitro-bone-model-that-mimics-glucocorticoid-induced-osteoporosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/generation-of-a-human-3d-in-vitro-bone-model-that-mimics-glucocorticoid-induced-osteoporosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology